Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 57-65

  de León Castañeda, Christian Díaz ^a   Altagracia Martínez, Marina ^a   Kravzov Jinich, Jaime ^a   Cárdenas Elizalde, Ma del Rosario ^a   Moreno Bonett, Consuelo ^a   Martínez Núñez, Juan Manuel ^a  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

Cost effectiveness; Hypoglycemic; Outpatients; Type 2 diabetes

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; MALE; META ANALYSIS; MEXICO; MONOTHERAPY; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PRIMARY HEALTH CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84859542292     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S27826     Document Type: Article

References (37)

1. González-Villalpando C, López-Ridaura R, Campuzano JC. González-Villalpando ME. The status of diabetes care in Mexican population: Are we making a difference? Results of the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52 Suppl 1:36-46.
2. Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major comorbidity in people with diabetes mellitus. CMAJ. 2003; 168(13):1661-1667.
3. Barceló A, Aedo C, Rjpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81(1):19-27.
4. International Diabetes Federation. Available from http://www.idf.org/. Accessed May 12, 2011.
5. International Diabetes Federation (IDF). Prevalence estimates of diabetes mellitus. 2010. Available from: http://www.diabetesatlas.org/downloads. Accessed February 24, 2011.
6. Rull JA, Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Perez FJ, Olaiz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res. 2005;36(3):188-196.
7. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. Salud Publica Mex. 2008;50(5):419-427.
8. Instituto Nacional de Estadística, Geografía e Historia (INEGI). Principales causas de defunción en México en el año 2008. [Principal reasons of death in Mexico in 2008.] 2010. Available from: http://www.inegi.org. mx/Sistemas/temasV2/Default.aspx?smest&ce17484. Accessed April 30, 2010.
9. Arredondo A, de Icaza E. Financial requirements for the treatment of diabetes in Latin America: implications for the health system and for patients in Mexico. Diabetologia. 2009;52(8):1693-1695.
10. Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case. Diabetes Care. 2004;27(1):104-109.
11. Consejo de Salubridad General. Edición 2008 del Cuadro Básico y Catálogo de Medicamentos (CByCM). Diario Oficial de la Federación (DOF). 25 de marzo del 2009. Tercera y Cuarta sección. [2008 edition of the Drug Essential List (CByCM). Federal Official Daily Gazette (DOF). March 25, 2009. Third and Fourth section.] Spanish.
12. Consejo de Salubridad General. Primera actualización de la Edición 2008 del Cuadro Básico y Catálogo de Medicamentos. Diario Oficial de la Federación (DOF). 08 de abril del 2009. Tercera sección. [First update of 2008 edition of the Essential Drug List (CByCM). Federal Official Daily Gazette (DOF). April 8, 2009. Third section.] Available from: http://www.ordenjuridico.gob.mx/Federal/PE/APF/APC/SSA/ Aclaraciones/2009/08042009%281%29.pdf. Accessed December 6, 2011. Spanish.
13. Muening P. Designing and Conducting Cost-Effectiveness Analyses in Medicine and Health Care. San Francisco, CA: Jossey-Bass; 2002.
14. Secretaría de Salud. Modificación a la Norma Oficial Mexicana NOM-015-SSA2-1994, Para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria para quedar como Norma Oficial Mexicana NOM-015-SSA2-1994, Para la prevención, tratamiento y control de la diabetes. Diario Oficial de la Federación (DOF). 18 de enero del 2001. Primera sección. [Modification to the Official Mexican Norm NOM-015-SSA2-1994, For the prevention, treatment and control of the diabetes mellitus in the primary care to stay as Official Mexican Norm NOM-015-SSA2-1994, For the prevention, treatment and control of the diabetes. Official diary of the Federation (DOF). January 18, 2001. First section.] Available from: http://www.sideso.df.gob.mx/ documentos/legislacion/NOM_015_SSA2.pdf. Accessed December 6, 2011. Spanish.
15. Gil LE, Domínguez ER, Sil MJ, Parrilla JI, de Santillana SP, Torres LP. Diagnóstico y tratamiento de la diabetes mellitus tipo 2 en el primer nivel de atención. México, Instituto Mexicano del Seguro Social. [Diagnosis and treatment of the diabetes mellitus type 2 in the primary attention level. Mexico, Mexican Social Security Institute], 2009. Spanish.
16. González CA, Valdez LA, Cruz EA, et al. Diagnóstico, metas de control ambulatorio y referencia oportuna de la diabetes mellitus tipo 2 en el primer nivel de atención. México, CENETEC-Secretaría de Salud. [Diagnosis, goals of outpatients control and opportune reference of the type 2 diabetes in the primary attention level. Mexico, CENETECMinistry of Health], 2008. Spanish.
17. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care. London, Royal College of Physicians, 2008. Available from: http:// www.nice.org.uk/nicemedia/pdf/CG66 NICEGuideline.pdf. Accessed December 6, 2011.
18. Grupo de trabajo de la Guía de Práctica Clínica sobre Diabetes tipo 2. Guía de Práctica Clínica sobre Diabetes tipo 2. Madrid, Agencia de Evaluación de Tecnologías Sanitarias del País Vasco, 2008. [Workgroup of the Clinical Practice Guide on type 2 diabetes. Clinical Practice Guide on type 2 diabetes. Madrid, Evaluation of Health Technologies Agency of the Basque Country, 2008.] Available from: http://www. guiasalud.es/GPC/GPC_429_Diabetes_2_Osteba_compl.pdf. Accessed December 6, 2011. Spanish.
19. PubMed. gov [database on the Internet]. Bethesda, MD: National Center for Biotechnology Information, US Library of Medicine; nd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed December 6, 2011.
20. SciVerse Scopus [database on the Internet]. Amsterdam: Elsevier; 2011. Available from: http://www.scopus.com/home.url. Accessed December 6, 2011.
21. The Cochrane Library [database on the Internet]. Hoboken, NJ: John Wiley and Sons; 2010. Available from: http://www.thecochranelibrary. com/view/0/index.html. Accessed December 6, 2011.
22. MEDLINE® [database on the Internet]. Bethesda, MD: National Library of Medicine; nd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed December 6, 2011.
23. Instituto Mexicano del Seguro Social (IMSS). Costos Unitarios por Nivel de Atención Médica para el año 2009. Diario Oficial de la Federación (DOF). 6 de marzo del 2009. [Unitary costs for Medical Attention Level. Federal Official Daily Gazette (DOF). March 6, 2009.] Available from: http://www.consultoriofiscalunam.com.mx/seccion-6-6. html. Spanish.
24. Instituto Mexicano del Seguro Social. Portal de Transparencia [Website of Transparent Information]. Available from: http://transparencia.imss. gob.mx/. Accessed June 23, 2009. Spanish.
25. Servicio de Administración Tributaria (SAT). Salarios Mínimos durante el 2009 [Minimum wages in 2009]. Available from: http://www.sat.gob. mx/sitio_internet/asistencia_contribuyente/informacion_frecuente/ salarios_minimos/45_13706.html. Accessed March 23, 2011. Spanish.
26. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-549.
27. Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol. 2003;40(1):20-27.
28. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glibenclamide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201-208.
29. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660-1665.
30. Fischer S, Patzak A, Rietzsch H, et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab. 2003;5(1):38-44.
31. Chan JC, Chan KW, Ho LL, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care. 1998;21(7):1058-1061.
32. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metforming libenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673-680.
33. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glibenclamide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab. 2002;4(6):368-375.
34. Saenz A, Fernández-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966.
35. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639.
36. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roquéi Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966.
37. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.